Objective To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …

The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines …

Background: In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction
in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …

• Evidence from randomized controlled trials has shown that nirmatrelvir–ritonavir and
monulpiravir likely reduce the risk of severe COVID-19, hospital admission and death in …

Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …

Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …

BACKGROUND The efficacy, effectiveness, and safety of the approved nirmatrelvir/ritonavir
regimen for treatment of laboratory-confirmed mild/moderately severe COVID-19 remains …

Background Treatment of coronavirus disease 2019 (COVID-19) with nirmatrelvir plus
ritonavir (NMV-r) in high-risk nonhospitalized unvaccinated patients reduced the risk of …

Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …